查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1138385

全球葡萄膜炎治療市場-2022-2029

Global Uveitis Treatment Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

主要驅動因素是葡萄膜炎發病率的上升、贈款和獎學金的存在以及研發活動的增加。

不斷增加的研發活動正在推動全球市場的增長。

根據臨床試驗，例如，越來越多的治療眼部炎症的臨床試驗正在全球範圍內進行。例如，由魯汶大學 (Universitaire Ziekenhuizen Leuven) 贊助的一項研究，旨在評估阿巴西普作為一種免疫抑制療法治療鳥擊性葡萄膜炎的療效和安全性，預計將於 2023 年 1 月 1 日在華盛頓大學醫學院完成五項試驗目前正在積極解決葡萄膜炎的干預措施，包括一項託法替尼治療炎症性眼病的研究，由 .由 Vastra Gotaland 地區贊助的研究，重點是預計將於 2022 年 12 月結束的葡萄膜炎患者的疏水性和親水性人工晶狀體的結果，由天津醫科大學張小米贊助 這包括一項 4 期試驗，測試英夫利昔單抗在臨床上可用於治療的假設難治性小兒葡萄膜炎患者，預計2022年12月完成。此外，已經招募了 35 項臨床試驗，表明全球市場的未來增長。

高成本、潛在的藥物副作用和嚴格的法規將阻礙全球葡萄膜炎治療市場的增長。

但是，預計高價格、與藥物相關的副作用以及缺乏對眼病的了解將抑制市場增長。預計流淚和炎症等藥物副作用也會阻礙市場增長。

行業分析

全球葡萄膜炎治療市場報告根據波特五力、研發、流行病學、監管、價格和管道分析等各種行業因素對市場進行了深入分析。

COVID-19 影響分析

在大流行期間，為遏制 COVID-19 的傳播實施了許多限制措施，這對全球市場產生了負面影響，擾亂了供需鏈並減少了葡萄膜炎治療藥物的銷售。此外，社會化法規使得定期進行眼科檢查變得困難，導致大多數葡萄膜炎患者未被發現，對全球葡萄膜炎藥物市場產生負面影響。

全球葡萄膜炎治療市場報告將提供對大約 40 多個市場數據表、45 多個數字和 200 頁（大約）的訪問。

內容

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 不斷發展的研發
      • 葡萄膜炎患者增加
      • 市場策略
    • 限制因素
      • 高成本
      • 藥物的副作用
      • 嚴格的監管機構
    • 商機
    • 影響分析

第五章行業分析

  • 波特五力分析
  • 流行病學分析
  • 研發
  • 管道分析
  • 供應鏈分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按治療類型

  • 腎上腺皮質類固醇
  • 免疫抑製劑
  • 單克隆抗體
  • 抗生素
  • 其他

第 8 章按疾病類型

  • 前葡萄膜炎
  • 後葡萄膜炎
  • 中間葡萄膜炎
  • 全葡萄膜炎

第 9 章原因

  • 非傳染性
  • 傳染性

第 10 章按銷售渠道

  • 醫院藥房
  • 零售藥房
  • 在線藥店

第 11 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 12 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準

第 13 章公司簡介

  • Bausch & Lomb Incorporated
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Santen Pharmaceutical Co., Ltd
  • AbbVie Inc.
  • Eyegate Pharmaceuticals, Inc.
  • Regeneron Pharmaceuticals
  • Eyepoint Pharmaceuticals Inc.
  • Alimera Sciences, Inc.
  • Clearside Biomedical, Inc.
  • Aldeyra Therapeutics, Inc

第14章 DataM

簡介目錄
Product Code: DMPH2170

Market Overview

Uveitis Treatment Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 5.9% during the forecast period (2022-2029).

Uveitis is an inflammation of the middle layer of an eye (uvea), also known as the uveal tract. Auto-immune disorders, injuries, inflammatory disorders, infections, and surgeries are common causes of uveitis. Common symptoms of uveitis include eye pain, eye floaters, blurred vision, increased sensitivity to light and redness of the eye.

Market Dynamics

The major driving forces are the rising incidence of uveitis, the presence of grants and fellowships, growing research and development activities.

The growing research and development activities are fueling the global market growth.

An increasing number of clinical trials for eye inflammation treatment are being conducted globally, for instance, according to the clinical trials. Gov currently, five different clinical trials are actively working on intervention for Uveitis, such as a study to estimate the efficiency and safety of Abatacept for Birdshot uveitis as an immunosuppressive treatment sponsored by Universitaire Ziekenhuizen Leuven and estimated completion on January 1, 2023, a study on Tofacitinib for the treatment of inflammatory eye disease sponsored by Washington University School of Medicine, a study focused on the outcome with the hydrophobic and hydrophilic intraocular lens in patients with and without uveitis sponsored by Vastra Gotaland Region and estimated completion on December 2022 and a phase 4 study to test the hypothesis that infliximab is clinically useful for patients with refractory childhood uveitis sponsored by Xiaomin Zhang, Tianjin Medical University and predicted completion by December 2022. Furthermore, 35 more clinical studies are recruiting, indicating the global market's future growth.

The high cost, chances of drug side effects and stringent regulations will be the demoting reasons for the global Uveitis Treatment market growth.

However, the high prices, the side effects associated with the medications, and the lack of knowledge regarding eye disorders are expected to restrain the market growth. Also, the side effects of medications like watery eyes and irritation will likely hamper the market growth.

Industry analysis.

The global uveitis treatment market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, research and developments, epidemiology, regulatory, pricing, and pipeline analysis.

COVID-19 Impact Analysis

During the pandemic, the global market was negatively affected as many restrictions were imposed to limit the COVID-19 spread, which led to the disruption of the supply and demand chain, reducing the sales of Uveitis Treatment. Furthermore, the socializing restriction made it difficult to get regular eye checkups, leaving most uveitis patients undetected, negatively impacting the global uveitis treatment market.

Segment Analysis

Corticosteroids are presumed to be prevailing throughout the forecast period (2022-2029)

The corticosteroid segment is expected to grow at a high rate since it is considered the mainstay treatment for patients with non-infectious uveitis. Corticosteroid drugs are very useful in minimizing inflammation. The FDA approved several corticosteroid eye drops available on the market. Ophthalmologists generally recommend eye drops, oral medications, or injections of corticosteroids. Corticosteroid implant is also increasingly gaining traction for people with chronic eye inflammation disorders. For instance, Retisert of Bausch+Lomb is the US's first FDA-approved surgical corticosteroid implant for treating non-infectious posterior uveitis. Many novel clinical trials are developing for uveitis. For instance, a phase 2 trial for the efficiency and safety of the Interleukin-17A inhibitor Izokibep (ABY-035) for treating a non-infectious intermediate, posterior or pan-uveitis (LINNAEA) sponsored by ACELYRIN Inc. and estimated to be complete by November 2022 and clinical study on Abatacept in Patients With Birdshot HLA A29 Uveitis: a phase II prospective 0pen label interventional proof-of-concept study sponsored by Universitaire Ziekenhuizen Leuven and estimated to be completed by January 1, 2023.

Geographical Analysis

The North American region is overshadowing the global uveitis treatment market.

North America dominated the Uveitis Treatment market in 2021. It is estimated to hold the largest market size over the forecast period (2022-2029), owing to an increase of approximately 15 cases per 100,000 population annually or some 38,000 new cases annually. It is a significant cause of blindness, accounting for 10-15% of all blindness in the United States, costing approximately $242 million annually. Furthermore, the NIH states that Uveitis is very common in the geriatric population and as the American geriatric population is growing at a high rate is contributing to its dominance over the market. For instance, as per the estimation from the U.S. Census Bureau, more than 56 million American adults aged 65 and older in the United States account for about 16.9% of the nation's population. By 2030, when the last person from the boomer generation ages into older adulthood, it is projected that there will be more than 73.1 million older adults.

Competitive Landscape

Competitive Landscape

The major players operating in the global uveitis treatment market are Bausch & Lomb Incorporated, Santen Pharmaceutical Co., Ltd, AbbVie Inc., Eyegate Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Eyepoint Pharmaceuticals Inc., Alimera Sciences, Inc., Clearside Biomedical, Inc., and Aldeyra Therapeutics, Inc. The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the uveitis treatment market globally. For instance, on May 8, 2020, AbbVie Inc. acquired Allergan plc. Also, on JUNE 2, 2022, Bausch + Lomb announced Launched Biotrue Hydration Plus, a multi-purpose solution.

Bausch + Lomb

Overview

Bausch + Lomb is a leading eye health products manufacturing company headquartered in Canada and was founded in 1853. It is among the world's largest suppliers of contact lenses, lens care products, pharmaceuticals, intraocular lenses, and other eye surgery products. Bausch + Lomb, on May 6, 2022, became a publicly traded company in 2021; around 21,000 employees were working for Bausch + Lomb.

Product Portfolio

Bausch + Lomb Company's uveitis product portfolio has XIPERE, VISUDYNE and RETISERT.

The global uveitis treatment market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Research and Development
      • 4.1.1.2. Growing Cases of Uveitis
      • 4.1.1.3. Market Strategies
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost
      • 4.1.2.2. Drug Side Effects
      • 4.1.2.3. Stringent Regulatory Bodies
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiological Analysis
  • 5.3. Research and Developments
  • 5.4. Pipeline Analysis
  • 5.5. Supply Chain Analysis
  • 5.6. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Treatment Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type Segment
    • 7.1.2. Market Attractiveness Index, By Treatment Type Segment
  • 7.2. Corticosteroids
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Immunosuppressant
  • 7.4. Monoclonal Antibodies
  • 7.5. Antibiotics
  • 7.6. Others

8. By Disease Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type Segment
    • 8.1.2. Market Attractiveness Index, By Disease Type Segment
  • 8.2. Anterior Uveitis
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Posterior Uveitis
  • 8.4. Intermediate Uveitis
  • 8.5. Panuveitis

9. By Cause

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cause Segment
    • 9.1.2. Market Attractiveness Index, By Cause Segment
  • 9.2. Non-Infectious
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Infectious

10. By Distribution Channels

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channels Segment
    • 10.1.2. Market Attractiveness Index, By Distribution Channels Segment
  • 10.2. Hospital Pharmacies
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Retail Pharmacies
  • 10.4. Online Pharmacies

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Disease Type
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Cause
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. The U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Disease Type
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Cause
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. The U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Disease Type
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Cause
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Disease Type
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Cause
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Disease Type
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Cause
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking

13. Company Profiles

  • 13.1. Bausch & Lomb Incorporated
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Santen Pharmaceutical Co., Ltd
  • 13.3. AbbVie Inc.
  • 13.4. Eyegate Pharmaceuticals, Inc.
  • 13.5. Regeneron Pharmaceuticals
  • 13.6. Eyepoint Pharmaceuticals Inc.
  • 13.7. Alimera Sciences, Inc.
  • 13.8. Clearside Biomedical, Inc.
  • 13.9. Aldeyra Therapeutics, Inc

LIST NOT EXHAUSTIVE

14. DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact